Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Transpl Infect Dis ; : e14274, 2024 Apr 04.
Artigo em Inglês | MEDLINE | ID: mdl-38576133

RESUMO

BACKGROUND: Hematopoietic stem cell transplant (HSCT) recipients are among patients with highest risk of adverse coronavirus disease 2019 (COVID-19) outcomes. OBJECTIVE: We compared clinical outcomes in post-HSCT patients with COVID-19 before and during the Omicron period. STUDY DESIGN: This was a retrospective study including patients post-HSCT with severe acute respiratory syndrome coronavirus 2 infection from April 2020 to March 2023 at Instituto Nacional de Cancerología, Mexico City. We describe their clinical characteristics and report the variables associated with severe clinical disease, hospitalization, and death. RESULTS: Fifty-three patients were included; 31 (58.5%) from the pre-Omicron period and 22 (41.5%) from the Omicron period. Median age was 42-years old (interquartile range 26-53), and 31 patients (59%) were men. Only four patients (16%) had received a vaccine prior to COVID-19 diagnosis in the pre-Omicron period versus 20 (91%) in the Omicron period (p < 0.001). COVID-19 severe cases were more common before Omicron: seven patients (23%) versus two patients (9%). Only one patient (3%) received an antiviral in the pre-Omicron period compared to 11 patients (50%) during the Omicron period (p < 0.01). COVID-19-associated mortality was almost double in the pre-Omicron period (16% vs. 9%, p = 0.6). CONCLUSIONS: This study reports patients with a high proportion of severe outcomes during the first 2 years of the pandemic. Outcomes improved during Omicron with better access to vaccines and antivirals and no in-hospital cases. Variables associated with worse outcomes were similar to other reports. Strengthening infection control measures in the hospital and better access to preventive strategies and therapeutic options are mandatory in these high-risk patients.

2.
Gac Med Mex ; 158(M3): M1-M48, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35350063

RESUMO

Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms of myeloid lineage that arise from the clonal expansion of their precursors in the bone marrow, interfering with cell differentiation, leading to a syndrome of bone marrow failure. AML is a consequence of genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, and arrangements in epigenetic changes that influence gene expression) in hematopoietic precursor cells, which create a clone of abnormal cells that are capable of proliferating but cannot differentiate into mature hematopoietic cells or undergo programmed cell death. The diagnosis requires more than 20% myeloid blasts in the bone marrow and certain cytogenic abnormalities. Treatment will depend on age, comorbidities, and cytogenetic risk among the most frequent.


La leucemia mieloide aguda (LMA) comprende un grupo heterogéneo de neoplasias de células hematopoyéticas de linaje mieloide que surgen de la expansión clonal de sus precursores en la médula ósea, interfiriendo con la diferenciación celular, lo que conlleva a un síndrome de falla medular. La LMA es una consecuencia de cambios genéticos y epigenéticos (mutaciones puntuales, rearreglos de genes, deleciones, amplificaciones y arreglos en cambios epigenéticos que influyen en la expression del gen) en las células hematopoyéticas precursoras, la cual crea una clona de células anormales que son capaces de proliferar, pero no se pueden diferenciar en células hematopoyéticas maduras ni sufrir una muerte celular programada. El diagnostic requiere más del 20% de blastos mieloides en médula ósea y ciertas anormalidades citogénicas. El tratamiento dependerá de la edad, comorbilidades, riesgo citogenético entre las más frecuentes.


Assuntos
Leucemia Mieloide Aguda , Diferenciação Celular , Consenso , Humanos , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/terapia , México
3.
Arana-Luna, Luara L.; Alvarado-Ibarra, Martha; Silva-Michel, Luis G.; Morales-Maravilla, Adrián; González-Rubio, María del C.; Chávez-Aguilar, Lénica A.; Tena-Iturralde, María Fernanda; Mojica-Balceras, Liliana; Zapata-Canto, Nidia; Galindo-Delgado, Patricia; Miranda-Madrazo, María Raquel; Morales-Hernández, Alba E.; Silva-Vera, Karina; Grimaldo-Gómez, Flavio A.; Hernández-Caballero, Álvaro; Bates-Martin, Ramón A.; Álvarez-Vera, José L.; Tepepa-Flores, Fredy; Teomitzi-Sánchez, Óscar; Fermín-Caminero, Denisse J.; Peña-Celaya, José A. de la; Salazar-Ramírez, Óscar; Flores-Villegas, Luz V.; Guerra-Alarcón, Lidia V.; Leyto-Cruz, Faustino; Inclán-Alarcón, Sergio I.; Milán-Salvatierra, Andrea I.; Ventura-Enríquez, Yanet; Pérez-Lozano, Uendy; Báez-Islas, Pamela E.; Tapia-Enríquez, Ana L.; Palma-Moreno, Orlando G.; Aguilar-Luévano, Jocelyn; Espinosa-Partida, Arturo; Pérez-Jacobo, Luis F.; Rojas-Castillejos, Flavio; Ruiz-Contreras, Josué I.; Loera-Fragoso, Sergio J.; Medina-Coral, Jesús E.; Acosta-Maldonado, Brenda L.; Soriano-Mercedes, Emely J.; Saucedo-Montes, Erick E.; Valero-Saldana, Luis M.; González-Prieto, Susana G.; Nava-Villegas, Lorena; Hernández-Colin, Ana K.; Hernández-Alcántara, Areli E.; Zárate-Rodríguez, Pedro A.; Ignacio-Ibarra, Gregorio; Meillón-García, Luis A.; Espinosa-Bautista, Karla A.; Ledesma de la Cruz, Cindy; Barbosa-Loría, Diego M.; García-Castillo, Carolina; Balderas-Delgado, Carolina; Cabrera-García, Álvaro; Pérez-Zúñiga, Juan M.; Hernández-Ruiz, Eleazar; Villela-Peña, Atenas; Gómez Cortés, Sue Cynthia; Romero-Rodelo, Hilda; Garzón-Velásquez, Katheryn B.; Serrano-Hernández, Cristina; Martínez-Ríos, Annel; Pedraza-Solís, María Luisa; Martínez-Coronel, Jorge A.; Narváez-Davalos, Iris M.; García-Camacho, Alinka S.; Merino-Pasaye, Laura E.; Aguilar-Andrade, Carolina; Aguirre-Domínguez, Juan A.; Guzmán-Mera, Pedro G.; Delgado-de la Rosa, Elizabeth; Flores López, Perla E.; González-Aguirre, Lilia L.; Ramírez-Alfaro, Edgar M.; Vera-Calderón, Heidi; Meza-Dávalos, María Lizeth; Murillo-Cruz, Juan; Pichardo-Cepín, Yayra M.; Ramírez-Romero, Eva F..
Gac. méd. Méx ; 158(spe): M1-M51, ene. 2022. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1375542

RESUMO

resumen está disponible en el texto completo


Abstract Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms of myeloid lineage that arise from the clonal expansion of their precursors in the bone marrow, interfering with cell differentiation, leading to a syndrome of bone marrow failure. AML is a consequence of genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, and arrangements in epigenetic changes that influence gene expression) in hematopoietic precursor cells, which create a clone of abnormal cells that are capable of proliferating but cannot differentiate into mature hematopoietic cells or undergo programmed cell death. The diagnosis requires more than 20% myeloid blasts in the bone marrow and certain cytogenic abnormalities. Treatment will depend on age, comorbidities, and cytogenetic risk among the most frequent.

4.
Bone Marrow Transplant ; 55(12): 2279-2285, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-32417853

RESUMO

The aim of this study was to assess the feasibility of hematopoietic cell transplantation (HCT) data collection using an electronic platform at Mexican centers. Four public centers performing HCT in adults were included. A cloud-based electronic platform in Spanish was developed to allow real-time registration of demographic, clinical, and outcomes variables. Data were obtained from paper and electronic medical records and institutional databases. Data managers were hired to perform the collection. Data from January 2015 to December 2018 were retro and prospectively collected during a 10-month period. From 2015 to 2018, 473 HCT were performed. Most were autologous (55%). Patients undergoing autologous HCT had the highest median age (49 years) compared with patients undergoing allogeneic (34 years) or haploidentical HCT (29 years). The most common underlying disease for autologous HCT was multiple myeloma. Acute leukemias were the most common diagnoses among allogeneic and haploidentical HCT recipients. Two-year nonrelapse mortality was 2.5%, 18%, and 18% for autologous, allogeneic, and haploidentical HCT, respectively. We determined it was feasible to start a multicenter collaborative study in Mexico as it was very well received by the physicians and it can lead to the creation of a Mexican HCT Registry in the near future.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Mieloma Múltiplo , Adulto , Humanos , México , Pessoa de Meia-Idade , Sistema de Registros , Condicionamento Pré-Transplante , Transplante Autólogo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...